Report from Industry Scientific Advisory Board

PPMI Annual Investigators Meeting
May 4-5, 2011

Igor Grachev, MD, PhD
ISAB Update

• What is ISAB?

• Who we are?
  – Chair: Igor Grachev, GE Healthcare
  – Kim Gallagher, GE Healthcare (secondary representative)
  – Michelle Collins, Abbot
  – Tom Comery, Pfizer
  – Susanne Ostrowizki, Roche (primary representative)
  – Paulo Fontoura, Roche (secondary representative)
  – Johan Luthman, Merck (primary representative)
  – Tony Ho, Merck (secondary representative)
  – Marcel van der Brug, Genentech
  – Bernard Ravina, Biogen Idec

• Stakeholder role of the ISAB
  – Strategic arm of Steering Committee
  – Input in Taskforces/Working groups
  – Participate in Annual Meeting and bi-monthly t-cons
  – Support Steering Committee
  – Suggest Ancillary Studies

• Why industry involvement is important and next steps?
PPMI Study Organization and Governance

PPMI Sites
- ISAB: Industry Scientific Advisory Board
- EAC: External Advisory Committee
- CSOC: Clinical Study Oversight Committee

PPMI Steering Committee
- MJFF: Michael J. Fox Foundation for PD Research

Core Components:
- Clinical Core
- Imaging Core
- Biorepository
- Bioinformatics Core
- Bioanalytics Core
- Genetics Core

Supporting Components:
- Statistics Core
- Biospecimen access
- Data access
Stakeholder Role of ISAB

- ISAB plays a critical role in providing input and strategic advice on study parameters and goals.
- All partner companies can have one primary designate and one secondary designate (to fill in when the primary cannot attend) to the ISAB.
- ISAB Chairmanship will rotate on an annual basis; Chairs are to be selected by the ISAB.
  - 1st Chair – GE Healthcare as first industry partner to sign up.
  - 2nd Chair – Pfizer.
- Acting and future chairs will participate in monthly Steering Committee calls and report back to ISAB colleagues.
- Each company can assign one primary and one secondary to Taskforces/Working Groups of interest.
- Each company can have two attendees at the Annual Meeting of the study.
- Support Steering Committee.
- Suggest Ancillary Studies.
ISAB Next Steps

• ISAB bi-monthly t-cons to formulate Goals and Objectives to support PPMI mission.

• Identify individuals within partner companies to integrate into taskforces/working groups. Ensure partner representation in working groups.

• Formulate and communicate ISAB members needs.

• Evaluate needs and gaps, and recommend new ancillary studies to accelerate drug development in PD, biomarkers acceptance by regulators, and develop new indications for approved products.

• Support PPMI in adding new ISAB members and in closing funding gaps.

• Finalize ISAB organization/working groups.